Globus Medical director Tobin sells $2.2M in shares
James R. Tobin, a director at Globus Medical Inc. (NASDAQ:GMED), sold 30,000 shares of Class A Common Stock for over $2.2 million on September 15, 2026, following the exercise of stock options. This sale, occurring near the stock's 52-week low, leaves Mr. Tobin with no direct beneficial ownership. The company recently reported mixed Q3 2026 results, with EPS slightly above estimates but revenue falling short due to product launch delays and weaker performance from its Nevro unit.
Globus Medical director Tobin sells $2.2M in shares By Investing.com
James R. Tobin, a director at Globus Medical Inc. (NASDAQ:GMED), sold 30,000 shares of Class A Common Stock for over $2.2 million on September 15, 2026, after exercising stock options. Following these transactions, Tobin no longer holds direct beneficial ownership of Class A Common Stock. This sale occurred while GMED stock is trading near its 52-week low, and comes amidst mixed Q3 2026 earnings, with EPS slightly beating estimates but revenue falling short.
Globus Medical director James R. Tobin sells $3.13 million in shares By Investing.com
James R. Tobin, a director at Globus Medical Inc. (NASDAQ:GMED), sold 41,666 shares of Class A Common Stock for over $3.13 million on November 10, 2026. This sale occurred while the stock was trading near its 52-week low, though Tobin also acquired an equal number of shares through stock options on the same day for approximately $2.34 million. Following these transactions, Tobin directly holds no Class A Common Stock.
Globus Medical (GMED) director Tobin exercises options and sells shares on November 10.
Globus Medical (GMED) director James R. Tobin exercised options for 41,666 Class A shares at various strike prices on November 10, 2026. Concurrently, he sold all 41,666 of these shares in two blocks at weighted average prices of $75.1025 and $75.6836 per share, resulting in approximately $786K in pre-tax spread. This transaction eliminated his direct holdings of both stock options and Class A common stock in the company.
Globus Medical Director Sold Shares Worth Over $3.1M
Globus Medical Director Tobin James R sold 41,666 shares of Class A Common Stock in two transactions on November 10, 2026, totaling over $3.1 million. The shares were sold at weighted average prices of $75.1025 and $75.6836 per share. Following these transactions, Tobin James R no longer directly owns shares of Globus Medical Class A Common Stock.
Globus Medical director James R. Tobin sells $3.13 million in shares
James R. Tobin, a director at Globus Medical Inc. (NASDAQ: GMED), sold 41,666 shares of the company's Class A Common Stock for over $3.13 million on November 10, 2026. This sale occurred while the stock was trading near its 52-week low, despite InvestingPro's analysis suggesting the company is undervalued. Concurrently, Mr. Tobin acquired 41,666 shares through stock option exercises for $2.34 million.
How Globus Medical Inc. Class A (GMED) Affects Rotational Strategy Timing
Globus Medical Inc. Class A (GMED) is currently experiencing weak near-term sentiment, which may indicate a resumption of long-term weakness after a neutral shift. AI models have generated three distinct trading strategies for GMED: a multi-week long position, a 1-5 day breakout strategy, and a tactical/swing short strategy, each with specific entry, target, and stop-loss levels. The analysis highlights a mid-channel oscillation pattern and an exceptional 31.9:1 risk-reward short setup.
Globus Medical Director James R. Tobin Announces Intent to Sell 41,666 Shares via Cashless Stock Option
Globus Medical Director James R. Tobin has filed a Form 144 notice to sell 41,666 shares of the company's common stock, valued at over $3.1 million. These shares were acquired through a cashless stock option exercise on November 10, 2026, and will be sold via Raymond James and Associates, Inc. This transaction follows a previous sale of 30,000 shares in September 2026.
Favorable Market Position and Emerging Surgical Technologies Underscore Globus Medical’s Narrow Moat
Globus Medical has established itself as the second-largest player in the $11 billion spine industry, holding approximately 20% market share following its 2023 merger with NuVasive and 2025 acquisition of Nevro. This strategic growth and diversification into spinal cord stimulation underscore its narrow moat. The company continues to gain market share through these significant mergers and acquisitions.
Globus Medical director Ann Rhoads sells $425,000 in shares By Investing.com
Ann D. Rhoads, a director at Globus Medical Inc. (NASDAQ:GMED), sold 5,000 shares of Class A Common Stock for $425,000 at a price of $85.00 each on November 4, 2026, pursuant to a pre-established trading plan. Following the sale, she directly holds 35,384 shares. Despite the insider sale occurring above the current trading price of $81.44, InvestingPro analysis indicates the stock is undervalued with a fair value of $112.54 and "EXCELLENT" financial health.
Globus Medical Boosts Share Buyback Program by $500M and Reports Q3 2026 Financial Results
Globus Medical, Inc. has announced a significant $500 million increase to its ongoing share repurchase program, bringing the total available for buybacks to approximately $611 million. This decision by the Board of Directors was disclosed in a Form 8-K filing to the SEC, alongside a press release detailing the company's sales and operational performance for the three and nine months ending September 30, 2026. The repurchase program has no set expiration date and offers flexibility in its execution.
Globus Medical director Ann Rhoads sells $425,000 in shares By Investing.com
Ann D. Rhoads, a director at Globus Medical Inc. (NASDAQ:GMED), sold 5,000 shares of Class A Common Stock for $425,000 on November 4, 2026, at a price of $85.00 per share. This transaction was part of a Rule 10b5-1 trading plan established in June 2026. The sale comes as Globus Medical's stock trades below the sale price, despite InvestingPro analysis indicating the stock is undervalued with an "EXCELLENT" financial health score.
At $85 a share, director Ann D. Rhoads sells 5,000 Globus Medical (GMED) shares.
Ann D. Rhoads, a director at Globus Medical, Inc. (GMED), sold 5,000 shares of Class A Common Stock at $85.00 per share on November 4, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan dated June 10, 2026. Following the sale, Rhoads directly holds 35,384 shares of the company.
Profit rose 18.7%, but Globus Medical (GMED) cut its 2026 revenue outlook.
Globus Medical reported mixed results for Q3 2026, with GAAP net income increasing by 18.7% to $141.2 million, but overall net sales slightly decreasing by 0.7% to $763.7 million. The company lowered its full-year 2026 revenue guidance to $3.09 billion from an earlier range, while reaffirming its non-GAAP diluted EPS guidance. Additionally, Globus Medical's board authorized an extra $500 million for share repurchases, with approximately $611 million remaining available.
Vanguard reports a stake below 5% in Globus Medical (GMED).
Vanguard Capital Management reported a beneficial ownership of 5,960,866 shares, representing 4.43% of Globus Medical Inc. (GMED) common stock, as of September 30, 2026. This filing indicates that Vanguard holds sole voting power over 885,307 shares and sole dispositive power over all 5,960,866 shares. The report explicitly states that Vanguard's ownership is below 5%, with no other single person's interest exceeding this threshold.
BlackRock reports a Globus Medical (GMED) stake with sole voting power over 10.3M shares.
BlackRock, Inc. has filed an amended ownership report for Globus Medical Inc. (GMED), disclosing beneficial ownership of 10,704,283 shares of Class A Stock, representing 8.0% of the class, as of September 30, 2026. The report indicates BlackRock holds sole voting power over 10,335,190 shares and sole dispositive power over all 10,704,283 beneficially owned shares. While various persons have rights to dividends or sale proceeds, no single person's interest exceeded 5% of the total outstanding common shares.
Globus Medical Inc Class A Estimates – HAM:GM0N
This page on TradingView provides financial estimates and data for Globus Medical Inc Class A (HAM:GM0N). Users can explore reported financial data, analyst estimates across various financial statements, and compare actual results with average, high, and low estimates. The platform also allows visualization of trends over time for income statements, balance sheets, cash flow, dividends, and earnings.
How Globus Medical Inc. Class A (GMED) Affects Rotational Strategy Timing
This article analyzes Globus Medical Inc. Class A (GMED) and its impact on rotational strategy timing, identifying weak near-term sentiment that could lead to bearish positioning. It details three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop levels. The analysis also provides multi-timeframe signal insights into support and resistance levels for GMED.
How Globus Medical Inc. Class A (GMED) Affects Rotational Strategy Timing
This article analyzes Globus Medical Inc. Class A (GMED) using AI models, highlighting a weak near-term sentiment and a mid-channel oscillation pattern. It outlines three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also provides multi-timeframe signal strengths and support/resistance levels for GMED.
Basic earnings per share (basic EPS) of Globus Medical Inc Class A – HAN:GM0N
This page provides basic earnings per share (EPS) information for Globus Medical Inc Class A, trading under the ticker GM0N on the Hannover Stock Exchange. The article focuses solely on financial data, indicating that the market was closed with no trades recorded at the time of publication. It serves as a data point for investors interested in the company's financial performance metrics.
Globus Medical (GMED) director sells shares not under preset trading plan
A director at Globus Medical (GMED), James R. Tobin, exercised fully vested options for 30,000 shares and subsequently sold all 30,000 Class A Common shares on September 15, 2026, at a weighted average price of $74.5834. The options exercised originated from grants in January 2024 and January 2022. This transaction was not conducted under a Rule 10b5-1 trading plan.
How (GMED) Movements Inform Risk Allocation Models
This article analyzes Globus Medical Inc. Class A (GMED) stock, noting a weak near-term sentiment despite long-term strength. It highlights an exceptional 59.8:1 risk-reward setup targeting a 17.4% gain with minimal risk, and outlines three AI-generated trading strategies for different risk profiles. The analysis includes multi-timeframe signal data for near, mid, and long-term horizons, advising on entry, target, and stop-loss levels.
Globus Medical Announces Acquisition of Higgs Boson Health to Transform Healthcare Experience Through AI-Driven Digital Solutions
Globus Medical, a musculoskeletal technology company, has acquired Higgs Boson Health, a digital healthcare experience company specializing in AI-driven solutions. This acquisition aims to enhance the patient and provider experience throughout the care journey, integrating Higgs Boson's technology into Globus Medical's surgical intelligence pillar to improve patient outcomes through continuous learning and analytics. The goal is to achieve 95% good outcomes for musculoskeletal surgeries within 10 years.
Globus Medical (GMED) Could Be 17% Undervalued On Its Robotics Growth Narrative
Globus Medical (GMED) is considered potentially undervalued despite strong historical returns and a P/E ratio below industry averages, driven by improved adjusted EBITDA margins. The company's fair value is estimated at $103.23 against a last close of $85.67, with growth expected from its robotics, navigation, and minimally invasive procedures, including the ExcelsiusGPS ecosystem and Excelsius XR headset. However, potential challenges include hospital capital spending and successful integration with NuVasive and Nevro.
Globus Medical Director Sold Shares Worth Over $2.1M
Stephen T. Zarrilli, a Director at Globus Medical (GMED), sold Class A Common Stock on August 18, 2026, totaling $2,175,965. The shares were sold at a weighted average price of $87.0386, ranging from $86.92 to $87.16. Following this transaction, Zarrilli no longer directly owns Class A Common Stock.
Globus Medical Director Stephen T. Zarrilli Executes Stock Options and Sells Shares on August 18, 2026
Globus Medical Director Stephen T. Zarrilli exercised stock options for 25,000 shares of Class A Common Stock on August 18, 2026, at $53.27 per share. On the same day, he sold all 25,000 shares at a weighted average price of $87.0386 per share, resulting in zero direct beneficial ownership of Globus Medical stock after the transactions. The options were granted in January 2020 and were fully vested.
Globus Medical (NYSE: GMED) director exercises options, sells 25,000 shares
Globus Medical (NYSE: GMED) director Stephen T. Zarrilli exercised 25,000 stock options at $53.27 per share and subsequently sold all 25,000 shares of Class A Common Stock at a weighted average price of $87.0386 per share. This transaction resulted in approximately $844,000 pre-tax spread for the director. The options were fully vested and granted on January 22, 2020.
Is Revenue Growth Amid Margin Pressure Altering The Investment Case For Globus Medical (GMED)?
Globus Medical (GMED) reported second-quarter 2026 results with increased sales but a decline in net income and EPS, reaffirming its full-year revenue outlook. The company's investment case hinges on translating revenue growth into durable profits amidst integration and cost control challenges from acquisitions. While revenue guidance remains firm, investors are urged to consider margin pressure and acquisition risks that could affect future profitability.
Is Globus Medical (GMED) Cheap After Its Earnings Beat And Higher EPS Outlook?
Globus Medical (GMED) has seen positive momentum with a 7.39% 90-day share price return following an earnings beat and higher EPS outlook. Despite a year-to-date dip, its 1-year total shareholder return is 40.41%. A valuation narrative suggests the stock is 23.3% undervalued, with a fair value of $107.42, driven by integration synergies and expected margin expansion from recent acquisitions.
Globus Medical (GMED) Stock Leans On Margin Gains As Nevro Recovery Lags
Globus Medical (GMED) reported a strong Q2 2026 with record non-GAAP earnings per share and a high adjusted EBITDA margin, indicating significant margin strength. Despite these gains, the company faces challenges with Nevro sales declining and robotics adoption being slower than anticipated, leading to some unmet operational milestones. The article suggests that while margin expansion is doing heavy lifting, investors should assess the company's cash generation and debt profile.
Is Rising Revenue But Weaker Margins Altering The Investment Case For Globus Medical (GMED)?
Globus Medical (GMED) recently reported Q2 2026 results showing increased revenue but decreased net income and diluted EPS, indicating margin compression. While the company reaffirmed its full-year revenue outlook, the focus has shifted to cost control and integration of acquisitions to improve profitability. The article suggests investors should consider both optimistic and cautious analyst views on future performance given the current margin pressures.
Globus Medical (NYSE: GMED) lifts 2026 EPS outlook on strong Q2 performance
Globus Medical (NYSE: GMED) announced strong second-quarter 2026 results, with worldwide net sales increasing by 5.9% to $789.6 million and non-GAAP diluted EPS rising 55.8% to $1.34. The company reaffirmed its 2026 revenue guidance of $3.18–$3.22 billion but raised its non-GAAP fully diluted EPS outlook to $4.95–$5.05, up from the previous range of $4.70–$4.80. This positive revision reflects improved profitability and disciplined execution, despite a GAAP EPS decline primarily due to a prior-year bargain purchase gain related to the Nevro acquisition.
Globus Medical Reports Second Quarter 2026 Results
Globus Medical reported strong second-quarter 2026 financial results, with worldwide net sales reaching $789.6 million, an increase of 5.9%. The company saw significant growth in US Spine and International Spine segments, contributing to a non-GAAP diluted EPS of $1.34, a 55.8% increase. Globus Medical also reaffirmed its full-year 2026 revenue guidance and updated its non-GAAP fully diluted EPS guidance upwards.
Is Globus Medical (GMED) Undervalued Or Is Its Recent Rebound Already Priced In?
Globus Medical (GMED) stock has seen renewed attention following a 7.84% gain over the last seven days, despite declines over the past 30 and 90 days. While the company's 1-year total shareholder return is positive at 52.33%, investors are debating whether the recent rebound indicates an undervalued stock or if the re-rating is complete. Simply Wall St's analysis suggests Globus Medical is undervalued with a fair value of $107.42, citing innovation in robotics and minimally invasive procedures, but also notes execution risks.
Globus Medical (GMED) Stock Could Be Undervalued Following Q2 Earnings Date
Globus Medical (GMED) stock has seen a significant return of 49.1% over the past year, yet current valuations suggest it may still be undervalued, particularly when considering its P/E ratio compared to the Medical Equipment industry and its peers. The company's tailored fair P/E multiple is estimated at 26.4x, higher than its current 18.6x, indicating a potential discount. The upcoming Q2 earnings release in early August will be crucial in shaping investor views on its growth prospects and whether the market will fully price in its fundamentals.
Kuehn Law probes Globus Medical executives for alleged self-dealing
Kuehn Law, PLLC has initiated an investigation into potential self-dealing and breaches of fiduciary duty by executives at Globus Medical, Inc. (NYSE: GMED). The firm is seeking damages and governance reforms for shareholders, offering free consultations to long-term investors concerned about potential misconduct. This legal probe could significantly impact the company's leadership and financial structure.
Globus Medical (GMED) director reports bona fide gift of 2,500 shares
Globus Medical director David D. Davidar reported a bona fide gift of 2,500 Class A Common Stock shares on July 27, 2026. This transaction was not part of a Rule 10b5-1 trading plan. Following the gift, Davidar directly holds 507,675 shares and indirectly owns 165,967 shares through the Davidar Family Irrevocable Trust for the benefit of his spouse and children.
Globus Medical Director David Davidar Transfers 2,500 Shares in Non-Sale Transaction
Globus Medical Director David Davidar transferred 2,500 shares of Class A Common Stock on July 27, 2026, as disclosed in a regulatory filing. This non-sale transaction reduced his direct beneficial ownership while his indirect holdings through a family trust remained significant. The disclosure offers insights into insider trading at the orthopedic implant and surgical robotics manufacturer.
Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating whether officers and directors of Globus Medical, Inc. (NYSE: GMED) breached their fiduciary duties to shareholders through potential self-dealing. The firm is encouraging long-term GMED stockholders to contact them to explore potential damages and corporate governance reforms, emphasizing that participation can contribute to market integrity. The consultation and case are free, with all costs covered by Kuehn Law.
Globus Medical Inc Class A Revenue Breakdown – DUS:GM0N
This article provides a revenue breakdown for Globus Medical Inc Class A (DUS:GM0N), highlighting its top-performing segment, Musculoskeletal Solutions, which generated €2.38 billion last year. The United States was the largest contributor to revenue, accounting for €2.02 billion. The company's total revenue for the last year was €2.50 billion.
Globus Medical Inc Class A Revenue Breakdown – TRADEGATE:GM0N
Globus Medical Inc Class A generated €2.50 billion in revenue last year, with its Musculoskeletal Solutions segment contributing the most at €2.38 billion. The majority of this revenue, €2.02 billion, came from the United States. This indicates a strong focus and performance in musculoskeletal solutions within the U.S. market.
ETFs Investing in Globus Medical Inc Class A Stocks
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Globus Medical Inc Class A stocks. The ETFs are sorted by market value and include details such as issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The information helps investors identify various funds that offer exposure to Globus Medical, Inc.
Kuehn Law investigates Globus Medical for potential fiduciary breaches
Kuehn Law, PLLC is investigating Globus Medical for potential fiduciary breaches and self-dealing by its officers and directors, encouraging long-term stockholders to seek damages and corporate governance reforms. The firm is offering free consultations and covers all case costs for investor clients, with Justin Kuehn, Esq. leading the inquiry. Shareholders are advised to act promptly due to potential time constraints on enforcing their rights, as the investigation focuses on potential misconduct and aims to recover losses and push for governance changes.
Globus Medical Schedules Second Quarter Earnings Release and Conference Call
Globus Medical, Inc. (NYSE:GMED) announced it will release its second quarter financial results for the period ended June 30, 2026, after market close on Thursday, August 6, 2026. The company will also host a teleconference at 4:30 p.m. Eastern Time on the same day to discuss its performance with the investment community. Details for accessing the webcast and telephone registration are provided on their investor relations website.
What Globus Medical (GMED)'s Robotics-Focused Institutional Interest Means For Shareholders
Globus Medical (GMED) has seen increased institutional interest due to its focus on robotics, navigation, and minimally invasive procedures, particularly its ExcelsiusGPS ecosystem. This renewed attention reinforces the company's investment narrative centered on durable growth from these technologies, with reaffirmed 2026 revenue guidance of US$3.18 billion to US$3.22 billion. The article suggests investors should consider whether its robotic platforms can translate this into high-margin recurring revenue, while also being aware of potential cost pressures and aggressive growth assumptions.
Globus Medical (GMED) Secures FDA Clearances As Revenue And R And D Stay Strong
Globus Medical (GMED) has secured new FDA clearances, expanding its product offerings in spine and orthopedic surgery. This development, coupled with strong revenue growth and a steady commitment to R&D, positions the company as an innovative and high-growth investment, especially when compared to competitors like Medtronic. An analysis by Simply Wall St suggests GMED shares are currently undervalued, trading significantly below analyst targets and their estimated fair value.
Globus Medical Inc Class A Actuals & Estimates (GETTEX:GM0N)
This article provides actuals and estimates for Globus Medical Inc Class A (GM0N) traded on GETTEX, including its current stock price, historical performance, analyst forecasts, and financial data. It covers revenue, earnings per share, net income, market capitalization, and volatility, along with information on upcoming earnings reports.
Globus Medical Inc Class A Actuals & Estimates (HAM:GM0N)
This article provides actuals and estimates for Globus Medical Inc Class A (HAM:GM0N), covering financial data from income statements, balance sheets, and cash flow statements, alongside analyst forecasts. It details the company's stock performance, market capitalization, earnings, revenue, and EBITDA. The report also addresses frequently asked questions regarding its stock price, ticker, volatility, and dividend policy.
Price to sales forward of Globus Medical Inc Class A – TRADEGATE:GM0N
This article provides the "Price to sales forward" for Globus Medical Inc Class A (GM0N) on the Tradegate Exchange. It highlights the current value, change, and percentage change for this financial metric. The information is presented within the context of TradingView's financial data offerings.
How Globus Medical Inc. Class A (GMED) Affects Rotational Strategy Timing
This article analyzes Globus Medical Inc. Class A (GMED) using AI models to provide trading strategies for different risk profiles. It highlights a strong near-term sentiment shifting to a long-term positive bias, with an impressive 53.9:1 risk-reward setup. The analysis offers specific entry, target, and stop-loss points for position trading, momentum breakout, and risk hedging strategies.